Tarsus Pharmaceuticals
NASDAQ: TARSFounded 2017 · Incorporated in Delaware · 440 employees on LinkedIn · 8 known investors
Find your way into Tarsus Pharmaceuticals
610 people in our graph share verified history with the Tarsus Pharmaceuticals team — schools, employers, funds. One of them is your warm intro.
Anthony Philippakisunlockedknows Bobak Azamian, MD, PhD · together at Brigham and Women's Hospital (overlapped)
knows the team · via Harvard Medical School
×3knows the team · via University of Oxford
×7knows the team · via Third Rock Ventures
Tarsus is a biopharmaceutical company focused on developing and delivering medicines that target the root cause of serious diseases with high unmet need, including eye conditions. Its treatment areas include Demodex blepharitis, and it works closely with eye care professionals and patients.
Founders & leadership
Tarsus Pharmaceuticals was founded in 2017 by Bobak Azamian, MD, PhD and Bobak Azamian.
BA
Bobak Azamian, MD, PhDinCo-founder · ChairmanBobak Azamian, an MD and PhD trained physician and scientist, co-founded Tarsus Pharmaceuticals in 2016 and serves as its Chairman and CEO. The company develops treatments for diseases with high unmet need and launched XDEMVY, an FDA-approved therapy for Demodex blepharitis, while advancing a pipeline spanning conditions such as ocular rosacea and Lyme disease prevention.
BA
Bobak AzamianinCo-founder · ChairmanBobak Azamian is co-founder, chairman, and CEO of Tarsus Pharmaceuticals, a biopharmaceutical company developing medicines for serious diseases including eye conditions such as Demodex blepharitis. A physician and scientist, he founded the company in 2016 and has led it through its public offering and clinical advances including the FDA approval of XDEMVY®.
JF
Jeffrey FarrowChief Financial Officer and Chief Strategy Officer
SN
Seshadri NeervannanChief Operating Officer
AM
Aziz MottiwalainChief Commercial Officer2020–2026Aziz Mottiwala is a healthcare executive with over 25 years of commercialization experience, including nearly 20 years in eye care across roles at Allergan (VP of Marketing, Eye Care Franchise), Opiant, Avanir, Valeant, and other pharmaceutical companies; he holds a BS in Biochemistry from UC San Diego and an MBA in Marketing and Finance from USC Marshall.
DW
Dianne WhitfieldinChief Human Resources OfficerDianne Whitfield is Chief Human Resources Officer at Tarsus Pharmaceuticals, a biopharmaceutical company developing treatments for serious diseases with high unmet need including eye conditions. She brings decades of experience in talent management, organizational effectiveness, leadership development, and strategic business partnership.
EY
Elizabeth Yeu-LinChief Medical Officer
Investors · 8
Funding
SEC filings, press & company announcements$125M disclosed across 1 of 3 rounds · 2019–2026
- $125MPIPE financingAug 2026 · 2 sourcesSource ↗
Source: company announcements and press reports — follow each round's link for the claim.
Valuation · disclosed
Disclosed events$311.9Mvaluation at IPOOct 2020 · $16.00/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
In the news
Tarsus secures USD 125m to fund Alkeus acquisition and expand eye care pipelineallsci.com · Aug 2026
Tarsus Pharmaceuticals Announces Oversubscribed $125 Million Private Placement Equity Financing | Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLPgunder.com · Aug 2026Frequently asked questions
- What does Tarsus Pharmaceuticals do?
- Tarsus is a biopharmaceutical company focused on developing and delivering medicines that target the root cause of serious diseases with high unmet need, including eye conditions. Its treatment areas include Demodex blepharitis, and it works closely with eye care professionals and patients.
- Who founded Tarsus Pharmaceuticals?
- Tarsus Pharmaceuticals was founded by Bobak Azamian, MD, PhD, Bobak Azamian in 2017.
- Who are Tarsus Pharmaceuticals's investors?
- Tarsus Pharmaceuticals's investors include APERTURE Venture Partners, Flying L Partners, Frazier Life Sciences, Visionary Ventures, Vivo Capital, Bain Capital Life Sciences, RTW Investments L.P., Visionary Venture.
- How much funding has Tarsus Pharmaceuticals raised?
- Tarsus Pharmaceuticals has disclosed $125M raised across 1 of its 3 known rounds.